PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 5, 2026Annals of Medicine0 citationsOpen Access

Association of SGLT2 inhibitors use with a lower risk of biliary diseases in patients with type 2 diabetes mellitus: a retrospective cohort study

View Full Paper
MGMing GaoZWZhenling WangKHKaiyue Hu

Key Points

  • This research aims to examine the relationship between SGLT2 inhibitor use and the risk of biliary diseases in patients with type 2 diabetes mellitus.
  • Conducted a retrospective cohort study of patients with type 2 diabetes mellitus
  • Analyzed the association between SGLT2 inhibitor use and biliary disease
  • Considered long-term treatment effects and high-risk subgroups
  • SGLT2 inhibitor use is associated with a lower risk of biliary diseases
  • Long-term treatment yields a more significant reduction in disease risk
  • Improved biliary biomarkers observed alongside reduced disease incidence

Abstract

SGLT2i use was associated with a lower BD risk in T2DM patients, particularly with long-term treatment and among high-risk subgroups. Improved biliary biomarkers paralleled this reduction, suggesting a potential link that warrants further study.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Gao et al. (2026) studied this question.

synapsesocial.com/papers/698434cff1d9ada3c1fb36d8https://doi.org/10.1080/07853890.2026.2619263
Ask AI
Helpful
Bookmark
Share
View Full Paper